Adjunctive semaglutide improves metabolic outcomes in patients with schizophrenia
The Brown University Psychopharmacology Update · 2026-03 · 37 (3) · 1-5
DOI: 10.1002/pu.31414 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Brown University Psychopharmacology Update, online erschienen am 23.02.2026.
Abstract (Originalsprache)
Weekly injections of semaglutide over 26 weeks were more effective than matching placebo in improving glycemic control and weight outcomes in patients with schizophrenia who received clozapine or olanzapine, a randomized trial has found. Participants receiving semaglutide did not experience a disproportionate number of adverse events. Study results were published online Dec. 3, 2025 in JAMA Psychiatry .
Zitieren
APA
(2026). Adjunctive semaglutide improves metabolic outcomes in patients with schizophrenia. The Brown University Psychopharmacology Update, 37(3), 1-5. https://doi.org/10.1002/pu.31414
Vancouver
Adjunctive semaglutide improves metabolic outcomes in patients with schizophrenia. The Brown University Psychopharmacology Update. 2026;37(3):1-5. doi:10.1002/pu.31414
BibTeX
@article{euvimed2026,
title = {Adjunctive semaglutide improves metabolic outcomes in patients with schizophrenia},
journal = {The Brown University Psychopharmacology Update},
year = {2026},
volume = {37},
number = {3},
pages = {1--5},
doi = {10.1002/pu.31414}
}
EUVIMED